A Pilot Study of All-Computational Drug Design Protocol–From Structure Prediction to Interaction Analysis

Speeding up the drug discovery process is of great significance. To achieve that, high-efficiency methods should be exploited. The conventional wet-bench methods hardly meet the high-speed demand due to time-consuming experiments. Conversely, in silico approaches are much more efficient for drug discovery and design. However, in silico approaches usually serve as a supportive role in research processes. To fully exert the strength of computational methods, we propose a protocol which integrates various in silico approaches, from de novo protein structure prediction to ligand-protein interaction simulation. As a proof of concept, human SK2/calmodulin complex was used as a target for validation. First, we obtained a predicted structure of SK2/calmodulin and predicted binding sites which were consistent with the literature data. Then we investigated the ligand-protein interaction via virtual mutagenesis, flexible docking, and binding affinity calculation. As a result, the binding energies of mutants have similar trends compared with the EC50 values (R = 0.6 for NS309 in V481 mutants). The results indicate that our protocol can be applied to the drug design of structure unknown proteins. Our study also demonstrates that the integration of in silico approaches is feasible and it facilitates the acceleration of new drug discovery.

[1]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[2]  W. Zhou,et al.  International Journal of Molecular Sciences Systems Pharmacology in Small Molecular Drug Discovery , 2022 .

[3]  Devadasan Velmurugan,et al.  Identification of Natural Compound Inhibitors for Multidrug Efflux Pumps of Escherichia coli and Pseudomonas aeruginosa Using In Silico High-Throughput Virtual Screening and In Vitro Validation , 2014, PloS one.

[4]  Jeremy R. Greenwood,et al.  Epik: a software program for pKa prediction and protonation state generation for drug-like molecules , 2007, J. Comput. Aided Mol. Des..

[5]  Thomas A. Halgren,et al.  Identifying and Characterizing Binding Sites and Assessing Druggability , 2009, J. Chem. Inf. Model..

[6]  Alexander D. MacKerell,et al.  Automation of the CHARMM General Force Field (CGenFF) II: Assignment of Bonded Parameters and Partial Atomic Charges , 2012, J. Chem. Inf. Model..

[7]  J. Kinney,et al.  Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains , 2015, Nature Biotechnology.

[8]  Ling Lu,et al.  α-Actinin2 cytoskeletal protein is required for the functional membrane localization of a Ca2+-activated K+ channel (SK2 channel) , 2009, Proceedings of the National Academy of Sciences.

[9]  D. Ramotar,et al.  A novel approach using C. elegans DNA damage-induced apoptosis to characterize the dynamics of uptake transporters for therapeutic drug discoveries , 2016, Scientific Reports.

[10]  Ming-Jing Hwang,et al.  Ligand-binding site prediction using ligand-interacting and binding site-enriched protein triangles , 2012, Bioinform..

[11]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[12]  Alexander D. MacKerell,et al.  Automation of the CHARMM General Force Field (CGenFF) I: Bond Perception and Atom Typing , 2012, J. Chem. Inf. Model..

[13]  L. Jardim,et al.  Riluzole in patients with hereditary cerebellar ataxia , 2016, The Lancet Neurology.

[14]  Alexander D. MacKerell,et al.  Extension of the CHARMM general force field to sulfonyl‐containing compounds and its utility in biomolecular simulations , 2012, J. Comput. Chem..

[15]  Jacob D. Durrant,et al.  Molecular dynamics simulations and drug discovery , 2011, BMC Biology.

[16]  Ralf Blossey,et al.  Molecular docking as a popular tool in drug design, an in silico travel , 2016, Advances and applications in bioinformatics and chemistry : AABC.

[17]  C. Glabe,et al.  Familial Alzheimer's Disease Mutations within the Amyloid Precursor Protein Alter the Aggregation and Conformation of the Amyloid-β Peptide* , 2017, The Journal of Biological Chemistry.

[18]  Robert Abel,et al.  Accelerating drug discovery through tight integration of expert molecular design and predictive scoring. , 2017, Current opinion in structural biology.

[19]  L. McNamee,et al.  Contribution of NIH funding to new drug approvals 2010–2016 , 2018, Proceedings of the National Academy of Sciences.

[20]  F. Orzi,et al.  Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial , 2015, The Lancet Neurology.

[21]  J. Skolnick,et al.  TM-align: a protein structure alignment algorithm based on the TM-score , 2005, Nucleic acids research.

[22]  R. Friesner,et al.  New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. , 2006, Bioorganic & medicinal chemistry.

[23]  Ming-Jing Hwang,et al.  Methods for predicting protein-ligand binding sites. , 2015, Methods in molecular biology.

[24]  R. Friesner,et al.  The VSGB 2.0 model: A next generation energy model for high resolution protein structure modeling , 2011, Proteins.

[25]  Woody Sherman,et al.  Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.

[26]  Torsten Schwede,et al.  SWISS-MODEL: homology modelling of protein structures and complexes , 2018, Nucleic Acids Res..

[27]  G. P. Sinha,et al.  Mutations in CIB2, a calcium and integrin binding protein, cause Usher syndrome type 1J and nonsyndromic deafness DFNB48 , 2012, Nature Genetics.

[28]  Jerry R. Hobbs,et al.  An Intracellular Allosteric Modulator Binding Pocket in SK2 Ion Channels Is Shared by Multiple Chemotypes. , 2018, Structure.

[29]  Antonio Lavecchia,et al.  Machine-learning approaches in drug discovery: methods and applications. , 2015, Drug discovery today.

[30]  R. Friesner,et al.  Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.

[31]  Alán Aspuru-Guzik,et al.  Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules , 2016, ACS central science.

[32]  Alexander D. MacKerell,et al.  CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..

[33]  Pratyush Tiwary,et al.  Prediction of Protein-Ligand Binding Poses via a Combination of Induced Fit Docking and Metadynamics Simulations. , 2016, Journal of chemical theory and computation.

[34]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[35]  Gerhard Wolber,et al.  The impact of molecular dynamics on drug design: applications for the characterization of ligand-macromolecule complexes. , 2015, Drug discovery today.

[36]  Torsten Schwede,et al.  The SWISS-MODEL Repository: new features and functionalities , 2005, Nucleic Acids Res..

[37]  Tom Halgren,et al.  New Method for Fast and Accurate Binding‐site Identification and Analysis , 2007, Chemical biology & drug design.

[38]  D. Strøbæk,et al.  CyPPA, a Positive SK3/SK2 Modulator, Reduces Activity of Dopaminergic Neurons, Inhibits Dopamine Release, and Counteracts Hyperdopaminergic Behaviors Induced by Methylphenidate1 , 2012, Front. Pharmacol..

[39]  Evan Bolton,et al.  PubChem 2019 update: improved access to chemical data , 2018, Nucleic Acids Res..

[40]  J. Pascal,et al.  Unstructured to structured transition of an intrinsically disordered protein peptide in coupling Ca2+-sensing and SK channel activation , 2013, Proceedings of the National Academy of Sciences.

[41]  Justin A. Lemkul,et al.  Parametrization of halogen bonds in the CHARMM general force field: Improved treatment of ligand-protein interactions. , 2016, Bioorganic & medicinal chemistry.

[42]  J. Adelman,et al.  SK channels in excitability, pacemaking and synaptic integration , 2005, Current Opinion in Neurobiology.

[43]  Woody Sherman,et al.  Use of an Induced Fit Receptor Structure in Virtual Screening , 2006, Chemical biology & drug design.

[44]  S. S. Imam,et al.  Computer Aided Drug Design: A Novel Loom To Drug Discovery , 2017 .

[45]  Jennifer L. Knight,et al.  OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. , 2016, Journal of chemical theory and computation.

[46]  George Hripcsak,et al.  Computational Drug Target Screening through Protein Interaction Profiles , 2016, Scientific Reports.

[47]  Christian Kramer,et al.  MM/GBSA Binding Energy Prediction on the PDBbind Data Set: Successes, Failures, and Directions for Further Improvement , 2013, J. Chem. Inf. Model..